Next Article in Journal
Serum Creatine Kinase-MB Isoenzyme Activity among Subjects with Uncomplicated Essential Hypertension: Any Sex Differences
Next Article in Special Issue
The Bronchiectasis Toolbox—A Comprehensive Website for the Management of People with Bronchiectasis
Previous Article in Journal
Efficacy of Pancreatic Endotherapy In Pancreatic Ascites And Pleural Effusion
Open AccessFeature PaperArticle

Exacerbations in COPD Patients with Bronchiectasis

Institute for Occupational Health of R. Macedonia—WHO Collaborating Center, 1000 Skopje, Macedonia
Institute for Epidemiology and Biostatistics, 1000 Skopje, Macedonia
Author to whom correspondence should be addressed.
Med. Sci. 2017, 5(2), 7;
Received: 7 February 2017 / Revised: 3 April 2017 / Accepted: 8 April 2017 / Published: 11 April 2017
(This article belongs to the Special Issue Selected Papers from the 1st World Bronchiectasis Conference)
There is evidence that coexisting bronchiectasis (BE) in patients with chronic obstructive pulmonary disease (COPD) aggravates the course of the disease. In this study, we aimed to evaluate the frequency and severity of bacterial exacerbations in COPD patients with BE. The frequency and duration of bacterial exacerbations treated in a 12‐month period, as well as the duration of the exacerbation‐free interval, were evaluated in 54 patients with COPD (Group D) who were diagnosed and assessed according to official recommendations. In 27 patients, BE was diagnosed by high‐resolution computed tomography (HRCT), whereas an equal number of COPD patients who were confirmed negative for BE by HRCT, served as controls. We found a significantly higher mean number of exacerbations in a 12‐month period in COPD patients with BE (2.9 ± 0.5), as compared to their mean number in controls (2.5 ± 0.3) (p = 0.0008). The mean duration of exacerbation, i.e. the mean number of days elapsed before complete resolution of the symptoms or their return to the baseline severity, was significantly longer in COPD patients with BE as compared to their mean duration in controls (6.9 ± 1.8 vs. 5.7 ± 1.4; p = 0.0085). In addition, the mean exacerbation‐free interval expressed in days, in patients with COPD with BE, was significantly shorter than in COPD patients in whom BE were excluded (56.4 ± 17.1 vs. 67.2 ± 14.3; p = 0.0149). Overall, our findings indicate that coexisting BE in COPD patients may lead to more frequent exacerbations with a longer duration. View Full-Text
Keywords: Bronchiectasis, COPD, exacerbation, HRCT Bronchiectasis, COPD, exacerbation, HRCT
Show Figures

Figure 1

MDPI and ACS Style

Minov, J.; Stoleski, S.; Mijakoski, D.; Vasilevska, K.; Atanasovska, A. Exacerbations in COPD Patients with Bronchiectasis. Med. Sci. 2017, 5, 7.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Search more from Scilit
Back to TopTop